Lymphology

Gamida Cell to Present at the BTIG Virtual Biotechnology Conference

Retrieved on: 
Tuesday, August 3, 2021

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that the company will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, August 10, 2021 at 3:00 p.m.

Key Points: 
  • Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that the company will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, August 10, 2021 at 3:00 p.m.
  • In the fourth quarter of 2021, Gamida Cell is targeting a BLA submission for omidubicel, the first potential approval of a cell therapy for blood cancer patients in need of an allogeneic bone marrow transplant.
  • Gamida Cell is an advanced cell therapy company committed to cures for patients with blood cancers and serious blood diseases.
  • For additional information, please visit www.gamida-cell.com or follow Gamida Cell on LinkedIn or Twitter at @GamidaCellTx.

Global Hematopoietic Stem Cell Transplantation Market to 2027 - Size, Share, Outlook, and Opportunity Analysis - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 3, 2021

The "Hematopoietic Stem Cell Transplantation (HSCT) Market - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hematopoietic Stem Cell Transplantation (HSCT) Market - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027" report has been added to ResearchAndMarkets.com's offering.
  • The global hematopoietic stem cell transplantation market is expected to witness significant growth during the forecast period owing to the increasing prevalence of leukemia and lymphoma.
  • Hematopoietic stem cell transplantation is a procedure in which multipotent hematopoietic stem cells sourced from peripheral blood cells, bone marrow, or umbilical cord blood are transplanted into the patient.
  • Hematopoietic stem cell transplantation is commonly used in the treatment of lymphoma (Hodgkin, Non-Hodgkin), leukemia, multiple myeloma, thalassemia, sickle cell anemia, and osteoporosis.

Jasper Therapeutics Announces Orphan Drug and Rare Pediatric Disease Designations for JSP191 for Conditioning Treatment Prior to Stem Cell Transplant

Retrieved on: 
Monday, June 14, 2021

Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to JSP191, a monoclonal antibody targeting the CD117 (stem cell factor) receptor, for conditioning treatment prior to hematopoietic stem cell transplantation.

Key Points: 
  • Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to JSP191, a monoclonal antibody targeting the CD117 (stem cell factor) receptor, for conditioning treatment prior to hematopoietic stem cell transplantation.
  • We believe JSP191 has the potential to safely and effectively expand lifesaving, curative stem cell transplant across multiple diseases.
  • The ongoing SCID clinical trial is evaluating JSP191 as a conditioning agent to enable stem cell transplantation in patients who are either transplant-naive or who received a prior stem cell transplant with a poor outcome.
  • In parallel, Jasper Therapeutics is advancing its preclinical engineered hematopoietic stem cell (eHSC) platform, which is designed to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts.

Atara Biotherapeutics Presents Positive Tab-cel® Long-Term Overall Survival Data for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease After Solid Organ Transplant at ATC 2021 Virtual Connect

Retrieved on: 
Monday, June 7, 2021

Data presented at EBMT 2021 demonstrated similar results in terms of overall survival in EBV+ PTLD patients who received tab-cel following hematopoietic cell transplantation (HCT).

Key Points: 
  • Data presented at EBMT 2021 demonstrated similar results in terms of overall survival in EBV+ PTLD patients who received tab-cel following hematopoietic cell transplantation (HCT).
  • Tab-cel was well-tolerated in this immunocompromised population with high disease burden and multiple comorbidities.
  • Atara understands the imperative to provide treatment options for these very sick, treatment-refractory and immunocompromised patients.
  • Atara is headquartered in South San Francisco and our leading-edge research, development and manufacturing facility is based in Thousand Oaks, California.

City of Hope Physicians and Scientists Present New Immunotherapy Research at ASCO Virtual Conference

Retrieved on: 
Thursday, June 3, 2021

8007 will be presented during an oral presentation at the ASCO conference on Tuesday, June 8, 8 to 11 a.m. EDT.

Key Points: 
  • 8007 will be presented during an oral presentation at the ASCO conference on Tuesday, June 8, 8 to 11 a.m. EDT.
  • A team of City of Hope scientists and researchers conducted a study using artificial intelligence to predict treatment response and survival in brain tumor patients.
  • City of Hope is an independent biomedical research and treatment center for cancer, diabetes and other life-threatening diseases.
  • Founded in 1913, City of Hope is a leader in bone marrow transplantation and immunotherapy such as CAR T cell therapy .

Magenta Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference

Retrieved on: 
Thursday, June 3, 2021

Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced that the company is scheduled to participate in a fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Thursday, June 10, 2021 at 4:40 p.m.

Key Points: 
  • Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced that the company is scheduled to participate in a fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Thursday, June 10, 2021 at 4:40 p.m.
  • A live webcast of the fireside chat can be accessed on the Magenta Therapeutics website at https://investor.magentatx.com/events-and-presentations .
  • The webcast replay will be available for 90 days following the event.
  • Magenta Therapeutics is a clinical-stage biotechnology company developing medicines to bring the curative power of stem cell transplant to more patients with blood cancers, genetic diseases and autoimmune diseases.

Seres Therapeutics to Present Clinical Research on the Microbiome’s Impact on Allogeneic Hematopoietic Stem Cell Transplantation and Cancer Immunotherapy at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Wednesday, May 19, 2021

b'Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that it will present the latest research from its early stage clinical development programs in two presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place virtually from June 4-8, 2021.

Key Points: 
  • b'Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that it will present the latest research from its early stage clinical development programs in two presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place virtually from June 4-8, 2021.
  • In an oral presentation, Seres will share data from its collaboration with the University of Cologne (K\xc3\xb6ln, Germany) assessing the association of the microbiome on clinical outcomes in allogeneic hematopoietic stem cell transplantation (HSCT) recipients.
  • Seres\xe2\x80\x99 SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA.
  • The SER-109 program is being advanced for the treatment of recurrent C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic.

Jasper Therapeutics Announces Updated 90-day Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation

Retrieved on: 
Wednesday, May 19, 2021

These data are consistent with pre-clinical work that demonstrated the capacity of JSP191 to target myelodysplastic cells and synergize with low doses of radiation.

Key Points: 
  • These data are consistent with pre-clinical work that demonstrated the capacity of JSP191 to target myelodysplastic cells and synergize with low doses of radiation.
  • \xe2\x80\x9cBased on this data and feedback from the FDA, we have now opened the dose-expansion phase of the study at the recommended Phase 2 dose.
  • JSP191, a first-in-class anti-CD117 monoclonal antibody, is in clinical development as a conditioning agent that clears hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplantation.
  • In parallel, Jasper Therapeutics is advancing its preclinical engineered hematopoietic stem cell (eHSC) platform, which is designed to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts.

Smart Immune Announces FDA Orphan Drug Status, IND Acceptance and Fast-Track Designation to Commence Phase 1/2 Clinical Trial of Proprietary Allogeneic T cell Progenitor Product SMART 101 (ProTcell™) for AML and ALL

Retrieved on: 
Monday, May 10, 2021

The FDA has also granted SMART 101 fast-track designation under its Expedited Program for Serious Conditions.

Key Points: 
  • The FDA has also granted SMART 101 fast-track designation under its Expedited Program for Serious Conditions.
  • Representing a decade of research and development, this is the first ever IND of any T cell progenitor product in the U.S.
  • The ALL/AML IND encompasses a clinical trial across adult and pediatric leukemia patients receiving T cell depleted allo-HSCT and will initially enroll up to 36 patients.
  • Smart Immune is initially targeting the pediatric orphan indication Severe Combined Immune Deficiency (SCID) & oncology (AML).

Castle Biosciences Presents Data at the Dermatology Nurses’ Association 2021 Annual Convention

Retrieved on: 
Thursday, April 22, 2021

b'Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced participation in the Dermatology Nurses\xe2\x80\x99 Association 2021 Annual Convention.

Key Points: 
  • b'Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced participation in the Dermatology Nurses\xe2\x80\x99 Association 2021 Annual Convention.
  • To predict likelihood of sentinel lymph node positivity, the Company utilizes its proprietary algorithm, i31-GEP, to produce an integrated test result.
  • Castle also has active research and development programs for tests in other dermatologic diseases with high clinical need.
  • Castle Biosciences is based in Friendswood, Texas (Houston), and has laboratory operations in Phoenix, Arizona.